ArticleTherapeutics and clinical risk management2007
A critical analysis of barriers to the clinical implementation of pharmacogenomics.
Article in Therapeutics and clinical risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.The pharmacogenomics journal · 2021Pooled it
- Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.Clinical pharmacology and therapeutics · 2017Pooled it
- Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.Advances in therapy · 2016Pooled it
- Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer.Clinical and translational science · 2026Article
- Toward Integration of Pharmacogenomic Tests into Daily Clinical Practice: A General Survey for Polish Healthcare Workers.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Pharmacogenomics in clinical trials: an overview.Frontiers in pharmacology · 2023Article
- Maturing pharmacogenomic factors deliver improvements and cost efficiencies.Cambridge prisms. Precision medicine · 2023Review
- What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?Frontiers in genetics · 2021Review
- Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Clinically relevant pharmacogenetic markers in Tatars and Balkars.Molecular biology reports · 2020Article
- Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings.Clinical and translational science · 2020Article
- CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study.Journal of cardiothoracic and vascular anesthesia · 2020Article
- Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.The pharmacogenomics journal · 2019Article
- Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications.Pharmacogenomics and personalized medicine · 2019Article
- Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.International journal of biomedical investigation · 2018Article
- Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.Pharmacogenetics and genomics · 2017Article
- Documenting Pharmacogenomic Testing with CPT Codes.Journal of AHIMA · 2016Article
- Economic evaluations of personalized medicine: existing challenges and current developments.Pharmacogenomics and personalized medicine · 2015Review
- Practical considerations in genomic decision support: The eMERGE experience.Journal of pathology informatics · 2015Article
- Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies.The pharmacogenomics journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over recent decades, basic research has yielded a large volume of data on many potentially clinically relevant genetic determinants of drug efficacy and toxicity. Until recently, most examples involved genes encoding drug-metabolizing enzymes, particularly the cytochromes P450. More recently, rapid advances in genomic technologies have enabled broader, genome-wide searches for determinants of drug response. In parallel with these pharmacogenetic studies, a new drug discovery platform, termed pharmacogenomics, has emerged which utilises genetic information to guide the selection of new drugs most likely to survive increasingly demanding safety and efficacy assessments. Together, these advances are widely promoted as the basis of a new era of drug-based therapeutics tailored to the individual. The extent to which individualized or personalized medicine will emerge as a sustainable new therapeutic paradigm is, however, the topic of much debate. It is clear that an increasingly complex series of barriers must be overcome if we are to successfully harness genomic advances in the clinical setting. Potential barriers may include cost-effectiveness of the test, ethical concerns over the use of DNA, and required educational and equipment infrastructure. Although long overdue, many of these potential barriers are now being subjected to closer examination and as a result, a framework for successful clinical uptake of pharmacogenomics is emerging.
Indexed as
Identifiers
18473000PMC2376080What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.